Interferon-λ inhibits immunopathology and boosts T cell–mediated immunity in a mouse model of mucosal viral infection
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci198863 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Emily Feng und 12 weiteren Autor:innen. Beteiligte Einrichtung: McMaster Immunology Research Centre, Department of Medicine and. Hauptthemen laut MEDLINE: Herpesvirus 2, Human, Herpes Genitalis, Immunity, Cellular, CD4-Positive T-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research.
Abstract (Originalsprache)
Interferon lambda (IFN-λ) has emerged as a critical inducer of immune regulation in addition to its mucosal antiviral properties. However, the cellular and molecular mechanisms that govern its dual role during viral infections remain unclear. Here, we discovered that mucosal delivery of IFN-λ abrogates the herpes simplex virus type 2–induced (HSV-2-induced) vaginal tissue pathology observed in the absence of type I IFN signaling, through drastically inhibiting IL-6 production. At the same time, we demonstrated that IFN-λ rescued local production of CD4 + T cell–dependent IFN-γ, which is essential for protection against the development of toxic megacolon following genital HSV-2 infection. Mechanistically, we found that IFN-λ enhances the differentiation of CCR2 + Ly6C hi cells into monocyte-derived antigen-presenting cells, thereby boosting T cell responses. In vivo depletion of CCR2 + cells abrogated this phenomenon. Together, these findings suggest that IFN-λ orchestrates a potent antiviral response, inhibiting hyperinflammatory responses while selectively augmenting effector T cell function. This study positions IFN-λ as a promising therapeutic candidate for enhancing local antiviral immunity and offers new insights into the regulation of immune responses in the context of mucosal viral infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- McMaster Immunology Research Centre, Department of Medicine and.
- Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada.
- University Hospital Regensburg, Department of Nephrology, Regensburg, Germany.
- Department of Microbiology, Biochemistry, and Molecular Genetics, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
- Department of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada.
- Centre for Discovery in Cancer Research, McMaster University, Hamilton, Ontario, Canada.
Förderung
- Canadian Institutes of Health Research
Zitieren
APA
Feng, E., Mansour, A., Balint, E., Mark, A., Tramonte, S., Monteiro, J. K., Read, M., Adaimy, M. J., Xing, Z., Mack, M., Kotenko, S. V., Santer, D. M., & Ashkar, A. A. (2026). Interferon-λ inhibits immunopathology and boosts T cell–mediated immunity in a mouse model of mucosal viral infection. Journal of Clinical Investigation. https://doi.org/10.1172/jci198863
Vancouver
Feng E, Mansour A, Balint E, Mark A, Tramonte S, Monteiro JK, et al. Interferon-λ inhibits immunopathology and boosts T cell–mediated immunity in a mouse model of mucosal viral infection. Journal of Clinical Investigation. 2026. doi:10.1172/jci198863
BibTeX
@article{Feng2026,
author = {Feng, Emily and Mansour, Alexa and Balint, Elizabeth and Mark, Alyssa and Tramonte, Sofia and Monteiro, Jonathan K and Read, Madison and Adaimy, Marie Joe and Xing, Zhou and Mack, Matthias and Kotenko, Sergei V and Santer, Deanna M and Ashkar, Ali A},
title = {Interferon-λ inhibits immunopathology and boosts T cell–mediated immunity in a mouse model of mucosal viral infection},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci198863}
}
EUVIMED